NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
ABM Therapeutics Corporation
Technische Universität Dresden
Netherlands Working Group on Immunotherapy of Oncology
University of Pittsburgh
Fondazione Melanoma Onlus
University Hospital Tuebingen
Georgetown University
University of Iowa
Melanoma Research Foundation Breakthrough Consortium